Frank P. McCormick, Ph.D., F.R.S., D. Sc.
Independent
Tenure on this board
New nominee
Meeting calendar
BBOT · Annual meeting · Tuesday, June 16, 2026
Bridgebio Oncology Therapeutics Inc
2 nominees · 2 ballot items.
Election of two Class I directors (Frank P. McCormick and Peter Lebowitz) and ratification of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$686M
1Y TSR
-24.4%
Board grade
C-
Record date
Apr 20, 2026
Filing
DEF 14A
Meeting concluded · Jun 16, 2026
Follow how the vote landed and what changed on Bridgebio Oncology Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class I Directors
ManagementBoard: FORVote to elect two Class I directors — Frank P. McCormick, Ph.D. and Peter Lebowitz, M.D., Ph.D. — to serve three-year terms expiring in 2029; Michelle Doig will not stand for re-election.
- 2
Ratification of Appointment of Deloitte & Touche LLP as Independent Registered Public Accounting Firm
ManagementBoard: FORVote to ratify the audit committee’s appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
0.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 22.3% | 17,878,594 | $160M |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 6.1% | 4,885,446 | $44M |
| 3 | Omega Fund Management, LLC | 4.1% | 3,289,661 | $29M |
| 4 | EcoR1 Capital, LLC | 3.5% | 2,823,126 | $25M |
| 5 | Alphabet Inc. | 3.5% | 2,823,126 | $25M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 3.5% | 2,818,348 | $25M |
| 7 | Enavate Sciences GP, LLC | 3.3% | 2,626,946 | $24M |
| 8 | CITADEL ADVISORS LLC | 3.2% | 2,528,762 | $23M |
| 9 | Novo Holdings A/S | 2.7% | 2,185,923 | $20M |
| 10 | Laurion Capital Management LP | 2.4% | 1,922,656 | $17M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bridgebio Oncology Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Bridgebio Oncology Therapeutics Inc 2026 annual meeting?
- Bridgebio Oncology Therapeutics Inc (BBOT) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.
- What is the record date for the Bridgebio Oncology Therapeutics Inc 2026 meeting?
- The record date for the Bridgebio Oncology Therapeutics Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bridgebio Oncology Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Bridgebio Oncology Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bridgebio Oncology Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Bridgebio Oncology Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.